Drugs / Fanastomig
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04618393 | Mar 2021 → Jul 2023 | cancer | Shanghai EpimAb Biotherapeutics Co., Ltd. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-07-07 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Regulatory EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06 epimab.com ↗
The company also announced the approval of its Investigational New Drug (IND) application for EMB-02 by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). |
| 2020-09-15 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Regulatory EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor epimab.com ↗
EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced that it has received “STUDY MAY PROCEED” letter from the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application for the Company’s second therapeutic development candidate, EMB-02. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-20 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics to Present Initial First-in-Human Data of EMB-02 at the 2023 ESMO Conference epimab.com ↗ |
| 2021-07-07 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06 epimab.com ↗ |
| 2020-09-15 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor epimab.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fanastomig | “Fanastomig (also known as EMB-02) is a bispecific antibody targeting programmed cell death protein-1(PD-1) and lymphocyte activation gene-3 (LAG-3), developed for the treatment...” PMID 40067130 ↗ Mar 2025 |
| Known as | EMB-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04618393 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314831 ↗ |
| Route | Intravenous | “once weekly (IV)” NCT04618393 ↗ |